The DTRF congratulates SpringWorks Therapeutics on this breakthrough drug approval and extends our deepest gratitude to everyone involved. Desmoid tumor patients, researchers, clinicians, the team at SpringWorks, and the DTRF all collaborated on this benchmark example of bringing a drug to an underserved patient population. An approval like this opens the door for continued research and interest in desmoid tumors. The DTRF will continue to aggressively fund research and collaborate with industry to accelerate the development of additional therapies toward a cure for each and every desmoid tumor patient.
The FDA and SpringWorks Therapeutics have also issued separate press releases about this important drug approval. Read more at these links:
FDA Press Release SpringWorks Therapeutics Press Release
6
Made with FlippingBook Online newsletter maker